Why the study?
Does flavopiridol improve response in patients with untreated or relapsed mantle-cell lymphoma?
Does flavopiridol improve response in patients with untreated or relapsed mantle-cell lymphoma?
Flavopiridol shows modest single-agent activity in mantle-cell lymphoma, suggesting it may be useful in combination with other agents or using different schedules.
Modest single-agent activity in mantle-cell lymphoma supports combination trials; leaves open its clinical role pending further study.
Flavopiridol given as a daily bolus for 3 consecutive days every 3 weeks has modest activity as a single agent for mantle-cell lymphoma. The number of stable and partial responses that was seen indicates that it is biologically active and may delay progression. Future studies in mantle-cell lymphoma should test this agent with other active agents and using different schedules.
No takes yet. Share an insight, caveat, or question.
Kouroukis et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: